柬埔寨：抗菌药物耐药性多部门行动计划（2025-2029年）

TABLE OF CONTENT ABBREVIATIONS ................................................................................................................................... iiMINISTERIAL MESSAGE ....................................................................................................................... iiiACKNOWLEDGEMENTS ....................................................................................................................... ivEXECUTIVE SUMMARY........................................................................................................................ viiCHAPTER1. BACKGROUND ................................................................................................................ 1GLOBAL CHALLENGE ................................................................................................................................................2GLOBAL RESPONSE...................................................................................................................................................3REGIONAL CHALLENGES ..........................................................................................................................................4CAMBODIA’S GENERAL HEALTH AND DEVELOPMENT STATUS AND IMPORTANCE OF AMR..............................5CAMBODIA’S CURRENT AMR STATUS......................................................................................................................7CAMBODIA’S CURRENT AMR APPROACH................................................................................................................9EVALUATING THE IMPLEMENTATION OF THE 2019-2023 MSAP-AMR................................................................12CHAPTER2. GOAL, PURPOSE AND OBJECTIVES .............................................................................. 18GOAL, PURPOSE, AND OBJECTIVES........................................................................................................................19CHAPTER3.HOW THE PLAN WAS DEVELOPED AND STAKEHOLDER ENGAGEMENT ................... 21CHAPTER 4. STRATEGIC AREAS, OBJECTIVES AND KEY RESULTS AREAS ......................................... 23STRATEGIC AREAS, OBJECTIVES AND KEY RESULTS AREAS..................................................................................24Strategic Area 1. Governance and coordination to reduce AMR .......................................................................25Workplan for strategic area 1 ...............................................................................................................................26Strategic Area 2. Evidence generation on AMR through surveillance, research, and strengthenedlaboratory capacity.................................................................................................................................................30Workplan for strategic area 2 ...............................................................................................................................33Strategic Area 3. Rational use of antimicrobial medicines.................................................................................41Workplan for strategic area 3 ...............................................................................................................................43Strategic Area 4. Containing AMR through good practices ................................................................................48Workplan for strategic area 4 ...............................................................................................................................50Strategic Area 5. Prevention and control of AMR through (risk) communication and communityengagement ............................................................................................................................................................53Workplan for strategic area 5 ...............................................................................................................................55CHAPTER5 ......................................................................................................................................... 57GUIDING PRINCIPLES ON IMPLEMENTING THE ACTIVITIES DEFINED IN THE MSAP-AMR ............ 57CHAPTER6 ......................................................................................................................................... 59MONITORING AND EVALUATION OF THE MSAP-AMR 2025-2029 ................................................... 59 ABBREVIATIONS AARAfter Action ReviewAMRAntimicrobialResistanceAMUAntimicrobial UseAMSAntimicrobial StewardshipC-CDCCambodian Communicable Disease ControlCamLISCambodia Laboratory Information SystemDHSDepartment of Hospital ServicesEQAExternal Quality AssuranceFAOFood and Agriculture OrganizationGAHPGood Animal Husbandry PracticesGAqPGood Aquaculture PracticesGDAHPGeneral Directorate of Animal Health and ProductionGHPGood Hygiene PracticesGMPGood Manufacturing